Zolis, make the board this promise. If (and I know, it's a big if) GNBT does succeed in a vaccine, in the NGIO spinout, or in any other venture that raises the price to where GNBT can uplist to NAS, you will write back to that author and point out the response you received today.

Tell them that if that is the best "analysis" they can do, they ought to consider another line of work.

I believe you'll be able to write that note within the 2020 calendar year, but then I've been one of the optimistic people around here that has had to keep pushing back my dates - so I have been wrong, wrong, WRONG (to quote a favorite CEO). So maybe I need to get into another line of investing myself....